Pages that link to "Q33380148"
Jump to navigation
Jump to search
The following pages link to Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (Q33380148):
Displaying 50 items.
- Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission (Q24187927) (← links)
- Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission (Q24202630) (← links)
- Targeted immunotherapy for acute myeloid leukemia (Q27687636) (← links)
- Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study (Q27851545) (← links)
- Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia (Q27851713) (← links)
- Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials (Q30249246) (← links)
- Histamine dihydrochloride: in the management of acute myeloid leukaemia (Q33393381) (← links)
- Spotlight on Histamine Dihydrochloride in Acute Myeloid Leukaemia† (Q33394612) (← links)
- Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia (Q33412609) (← links)
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy (Q33717707) (← links)
- Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia (Q33881750) (← links)
- IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study (Q33897586) (← links)
- Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808 (Q34069811) (← links)
- The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling (Q34171983) (← links)
- Acute myeloid leukaemia in adults (Q34327218) (← links)
- Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission (Q34630588) (← links)
- Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria (Q35018521) (← links)
- Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia (Q35210494) (← links)
- NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma (Q35605318) (← links)
- Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia (Q36457184) (← links)
- Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia (Q36597388) (← links)
- Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia (Q36925156) (← links)
- Treatment of acute myeloid leukemia with 20-30% bone marrow blasts (Q36934199) (← links)
- Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients (Q37065843) (← links)
- Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. (Q37289691) (← links)
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). (Q37334588) (← links)
- Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). (Q37558778) (← links)
- Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation (Q37564774) (← links)
- Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. (Q37571981) (← links)
- Immunotherapy prospects for acute myeloid leukaemia (Q37763280) (← links)
- Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia (Q37810123) (← links)
- Upfront therapy of acute myeloid leukemia. (Q37897183) (← links)
- Acute myeloid leukemia: focus on novel therapeutic strategies. (Q38015336) (← links)
- Current strategies in immunotherapy for acute myeloid leukemia (Q38068967) (← links)
- Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. (Q38161965) (← links)
- Optimal therapy for adult patients with acute myeloid leukemia in first complete remission (Q38208953) (← links)
- Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia (Q38769960) (← links)
- The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia (Q38892311) (← links)
- Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia (Q38918850) (← links)
- The antiviral effects of acteoside and the underlying IFN-γ-inducing action (Q40689926) (← links)
- Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia (Q41509184) (← links)
- Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. (Q41527981) (← links)
- Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy (Q42683573) (← links)
- New agents in post-remission therapy (Q42786187) (← links)
- Addressing the Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 in Treating Acute Myeloid Leukemia: A Bayesian Meta-Analysis (Q51581573) (← links)
- Histamine H2 Receptor in Blood Cells: A Suitable Target for the Treatment of Acute Myeloid Leukemia (Q51696870) (← links)
- Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission (Q57898894) (← links)
- Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and Megakaryocytic Dysplasia (Q58459239) (← links)
- Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (Q58554859) (← links)
- Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically (Q64116651) (← links)